| Identification | Back Directory | [Name]
2H-Indazole, 2-[(2-chloro-4-fluorophenyl)Methyl]-3-(4-fluorophenyl)-7-(trifluoroMethyl)- | [CAS]
875787-07-8 | [Synonyms]
LXR623
CS-758
WAY 252623
LXR623/LXR-623
LXR-623 (WAY-252623)
WAY-252623;LXR623;LXR 623;WAY252623;WAY 252623
2-[(2-chloro-4-fluorophenyl)Methyl]-3-(4-fluorophenyl)-7-(trifluoroMethyl)-
2-[(2-Chloro-4-fluorophenyl)methyl]-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole
2H-Indazole, 2-[(2-chloro-4-fluorophenyl)Methyl]-3-(4-fluorophenyl)-7-(trifluoroMethyl)-
2-[(2-Chloro-4-fluorophenyl)methyl]-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole WAY 252623 | [Molecular Formula]
C21H12ClF5N2 | [MDL Number]
MFCD16495812 | [MOL File]
875787-07-8.mol | [Molecular Weight]
422.78 |
| Chemical Properties | Back Directory | [Melting point ]
93℃ | [Boiling point ]
528.4±50.0 °C(Predicted) | [density ]
1.40 | [storage temp. ]
room temp | [solubility ]
DMSO:50.0(Max Conc. mg/mL);118.26(Max Conc. mM)
Ethanol:52.0(Max Conc. mg/mL);123.0(Max Conc. mM) | [form ]
powder | [pka]
-1.87±0.30(Predicted) | [color ]
white to beige | [InChI]
1S/C21H12ClF5N2/c22-18-10-15(24)9-6-13(18)11-29-20(12-4-7-14(23)8-5-12)16-2-1-3-17(19(16)28-29)21(25,26)27/h1-10H,11H2 | [InChIKey]
KYWWJENKIMRJBI-UHFFFAOYSA-N | [SMILES]
FC(F)(F)c1c2n[n](c(c2ccc1)c4ccc(cc4)F)Cc3c(cc(cc3)F)Cl |
| Safety Data | Back Directory | [RIDADR ]
UN 2811 6.1 / PGIII | [WGK Germany ]
WGK 3 | [Storage Class]
6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | [Hazard Classifications]
Acute Tox. 3 Oral |
| Hazard Information | Back Directory | [Uses]
WAY 252623 is a novel and potent LXR (liverX receptor) β-agonist used as a potential candidate for the treatment of atopic dermatitis. | [Biochem/physiol Actions]
WAY-252623 (LXR623) is an orally available, potent and highly selective Liver X receptors (LXRs) agonist that significantly reduced total and LDL-cholesterol. WAY-252623 reduces lesion progression in the murine LDLR(-/-) atherosclerosis model. | [in vivo]
LXR-623 (400 mg/kg, p.o.) crosses the blood-brain barrier, induces target gene expression, and achieves therapeutic levels in GBM cells in the brain with minimal activity in the periphery. LXR-623 inhibits tumor growth, promotes tumor cell death, and prolongs the survival of mice bearing intracranial patient-derived GBMs[1]. LXR-623 (1.5, 5 mg/kg/day) significantly reduces progression of atherosclerosis in animals compared with the placebo group[2]. WAY-252623 (15 and 50 mg/kg) results in a significant reduction of atherosclerosis in a dose-dependent manner. WAY-252623 (20, 60, and 120 mg/kg/day, p.o.) displays neutral lipid effects in this CETP-expressing Syrian hamster[3]. Moreover, LXR-623 (50 mg/kg) induces gene expression in rodent peripheral blood cells in rat. LXR-623 (0, 15 and 50 mg/kg) dose-dependently upregulates transcription of ABCA1 and ABCG1 in monkey whole blood cells proportional to dose[4]. | [storage]
Store at -20°C |
|
|